Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study-Reference-Cited by-同舟云学术

Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

Published:2023-09 Issue:3 Volume:84 Page:321-330
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Abida Wassim^ORCID,Campbell David,Patnaik Akash,Bryce Alan H.,Shapiro Jeremy,Bambury Richard M.,Zhang Jingsong,Burke John M.,Castellano Daniel,Font Albert,Ganju Vinod,Hardy-Bessard Anne-Claire,McDermott Ray,Sautois Brieuc,Spaeth Dominique,Voog Eric,Piulats Josep M.,Pintus Elias,Ryan Charles J.,Merseburger Axel S.,Daugaard Gedske,Heidenreich Axel,Fizazi Karim,Loehr Andrea,Despain Darrin,Simmons Andrew D.,Dowson Melanie,Go Jowell,Watkins Simon P.,Chowdhury Simon

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. Prostate cancer and PARP inhibitors: progress and challenges;Teyssonneau;J Hematol Oncol,2021

2. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration;Abida;J Clin Oncol,2020

3. Genomic testing in patients with metastatic castration-resistant prostate cancer: a pragmatic guide for clinicians;Merseburger;Eur Urol,2021

4. Rubraca® (rucaparib) tablets [prescribing information]. Boulder, CO: Clovis Oncology, Inc.; 2022.

5. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study;Abida;Clin Cancer Res,2020

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing;ESMO Open;2024-09

2. Multicenter non-interventional study of prevalence of homologous recombination gene mutations and approaches to treatment of metastatic castration-resistant prostate cancer in Russia (ADAM);Cancer Urology;2024-08-17

3. Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials;Exploration of Targeted Anti-tumor Therapy;2024-08-02

4. Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies;2024-07-19

5. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group;Annals of Oncology;2024-07